CHPA Reiterates Call for Additional Measures on Dietary Supplement Provisions in Draft User Fee Reauthorization Package

CHPA’s President & CEO, Scott Melville, released the following statement in response to the FDA Safety and Landmark Advancement (FDASLA) Act of 2022:
Share page:

“The discussion draft of this bill takes steps needed to provide consumers with more information and greater transparency into products they rely on every day, including dietary supplements and cosmetics. CHPA appreciates the open, collaborative, and bipartisan process afforded by the leadership of the Senate HELP Committee. On cosmetics reform, CHPA appreciates the important regulatory clarity the draft offers.

“However, we believe that the dietary supplement provisions need amending and that the bill language should go further to provide consumers additional assurances regarding the safety and integrity of dietary supplements sold in the U.S.

“CHPA looks forward to continuing to work with Congress as the FDASLA Act moves through the legislative process.”

The Consumer Healthcare Products Association (CHPA), founded in 1881, is the national trade association representing the leading manufacturers and marketers of consumer healthcare products, including over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices. CHPA is committed to empowering self-care by ensuring that Americans have access to products they can count on to be reliable, affordable, and convenient, while also delivering new and better ways to get and stay healthy. Visit